SynthesisHerz2022
Association between MTHFR C677T polymorphism and risk of coronary artery disease in the Chinese population: meta-analysis.
Synthesis in Herz, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- The Effect of the MTHFR C677T Genotype Polymorphism on the Efficacy of Folic Acid Treatment for Hyperhomocysteinemia and Cardiovascular Endothelial Function.Chronic diseases and translational medicine · 2026Article
- One-carbon metabolism and cardiovascular disease: Molecular mechanisms, genetic influences, and epigenetic regulation.Biochemistry and biophysics reports · 2026Review
- Guidance and Position of RINN22 regarding Precision Nutrition and Nutriomics.Lifestyle genomics · 2025Review
- Association Study ofCardiology research and practice · 2025Article
- Homocysteine concentration in coronary artery disease and severity of coronary lesions.Journal of cellular and molecular medicine · 2024Article
- ALDH2 rs671 and MTHFR rs1801133 polymorphisms are risk factors for arteriosclerosis in multiple arteries.BMC cardiovascular disorders · 2023Article
- Development of a Prognostic Model for MACE in Atherosclerosis Based on MTHFR and Serum Markers.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisObservational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrevious studies have investigated the close association between the MTHFR C677T polymorphism and the risk of coronary heart disease (CAD) in the Chinese population. However, the results remain inconclusive. Therefore, this meta-analysis was performed to derive a more precise estimate of these associations.
methodsOdds ratios (OR) with 95% confidence intervals (CI) were used to assess the relationship between the MTHFR C677T polymorphism and the risk of CAD. Studies were identified by searching the literature for articles published before 2017.
resultsA total of 39 studies comprising 12,101 individuals (6117 cases and 5984 controls) were included. For the allelic model T vs. C, the pooled OR was 1.43 (95% CI: 1.30-1.57, p < 0.0001); for the recessive model TT vs. CC + TC, the pooled OR was 1.48 (95% CI: 1.29-1.70, p < 0.0001); for the dominant model TT + TC vs. CC, the pooled OR was 1.65 (95% CI: 1.43-1.89, p < 0.0001).
conclusionIn the subgroup analysis of high-quality studies, an obvious association was observed between the MTHFR C677T polymorphism and CAD risk in the Chinese population.
Indexed as
Identifiers
35089369What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.